The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, biosimilars of Roche’s Avastin (bevacizumab), Roche’s Herceptin (trastuzumab), and AbbVie’s Humira (adalimumab) have launched in the market, and many others are in late-phase development. China has a high disease burden of cancer and immunological diseases, and the country bears the highest global footprint of many such illnesses. With several high-selling biologics used to treat these diseases losing patent protection, many domestic and multinational companies are developing biosimilars to compete in this highly lucrative space. Moreover, to curb the increasing healthcare cost and strengthen quality control, China has provided improved regulatory guidance on biosimilars development and is promoting volume-based procurement (VBP) programs to bring high-quality, cost-effective generics and biosimilars to the market. We expect the robust competition and government support to lead the biosimilars market of China to grow significantly over the forecast period.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with medical oncologists and immunologists / rheumatologists. Supported by survey data collected for this and other DRG research.
Ten-year, annualized, drug-level sales and patient shares of key oncology and immunology biosimilars and branded agents, through 2029, based on primary and secondary market research to formulate patient uptake assumptions.
Phase III/PR: 50+ agents; Phase II: 5+ agents; coverage of select early-phase products.